HOME2025-01-14T12:25:37+00:00

Fighting bacterial infections and resistance

QureTech Bio develops new synthetic antibacterial agents that address significant medical need in infectious disease. The compounds are new small molecules from a well-developed chemical platform that are protected by strong intellectual property.

The company’s lead program is focused on developing a new class of antibiotics. The GmPcides are bactericidal against Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus pyogenes and Enterococcus ssp, including drug-resistant strains such as MRSA and VRE. No resistance development has been detected in vitro or in clinical isolates. Read more about the GmPcide program here.

Antimicrobial resistances 

– a major threat to global
health

GmPcides

– a new class of antibiotics effective against multidrug resistant Gram-positive bacteria

The market dynamics for new antibiotics have started to change, and QureTech Bio is well positioned to contribute with valuable new therapeutic options

Latest News

Contact

Welcome to contact us for more information about partnership opportunities.

Fredrik Almqvist, Quretech Bio

MARKUS THOR
CEO
markus.thor@quretech.com
+46 70 644 99 91

Annica Rönnbäck, Quretech Bio

ANNICA RÖNNBÄCK
COO
annica.ronnback@quretech.com

Go to Top